Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Dermatologic 2Thoracic 1Plasma cell 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Recurrence 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1

Interventions

Cyclophosphamide 3fludarabine phosphate 2fludarabine 2Sorafenib 2Oxaliplatin 2Leucovorin 2Interleukin-2 2Fluorouracil 2Denosumab 2Bortezomib 2Bevacizumab 2venetoclax 1vactosertib 1trametinib 1temsirolimus 1sargramostim 1ruxolitinib 1repotrectinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1enzalutamide 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × ALT-801 × Plasma cell × Clear all
NCT01670994 2024-06-18

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Altor BioScience

Phase 1/2 Terminated
6 enrolled 10 charts
Plasma cell

Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡